Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy

Next Previous
Search
Trial Profile

Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 18F-fluoroestradiol (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Diagnostic use
  • Sponsors Zionexa

    • Most Recent Events

    • 10 Jun 2024 Status changed from recruiting to discontinued.
    • 10 Dec 2022 Trial design, presented at the 45th Annual San Antonio Breast Cancer Symposium
    • 08 Oct 2022 Planned initiation date changed from 30 Sep 2022 to 31 Oct 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top